[(89)Zr]Oxinate4 for long-term in vivo cell tracking by positron emission tomography
- Submitting institution
-
King's College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 112406946
- Type
- D - Journal article
- DOI
-
10.1007/s00259-014-2945-x
- Title of journal
- European journal of nuclear medicine and molecular imaging
- Article number
- -
- First page
- 278
- Volume
- 42
- Issue
- -
- ISSN
- 1619-7089
- Open access status
- Out of scope for open access requirements
- Month of publication
- October
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
8
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Cell-based therapies are revolutionising medicine. Understanding trial outcomes requires tracking of the fate of administered cells in vivo. Scintigraphy with 111In- or 99mTc-labelled cells is established clinically but has inadequate resolution and quantification. PET is superior, raising an unmet need for cell labelling with long half-life positron emitters. This paper introduces the first such tracer, which is now in use worldwide preclinically https://doi.org/10.2967/jnumed.117.206714; https://doi.org/10.1148/radiol.15142849) and in clinical trials (NCT03807973; NCT03298763). We filed a patent (June 2020) for a commercialisable kit-based version. It underpins major grants (WT203148/Z/16/Z; EP/S032789/1; EP/R045046/1). We have also adapted it for tracking liposomal nanomedicines (https://doi.org/10.1016/j.ymthe.2018.10.006; https://doi.org/10.2147/IJN.S134379; https://doi.org/10.1021/acsnano.6b05935).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -